Literature DB >> 21778133

Gene therapy of liver diseases: a 2011 perspective.

Gloria Gonzalez-Aseguinolaza1, Jesús Prieto.   

Abstract

Liver diseases including inherited metabolic disorders, chronic viral hepatitis, liver cirrhosis and primary and metastatic liver cancer constitute a formidable health problem because of their high prevalence and the important limitations of current therapies. Gene therapy, a procedure based on the transfer of therapeutic genes to tissues, has been used since the 1990s as a new approach to treating a number of incurable conditions. After a period of lights and shades recent success in treating several devastating diseases like inherited immune deficiency disorders, beta-thalassemia, or inherited blindness appear to herald a new era where gene therapy can be listed among standard therapy options for a wide variety of human conditions. In this review, we provide information illustrating the potentiality of gene therapy in the management of liver diseases lacking other effective therapies.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21778133     DOI: 10.1016/j.clinre.2011.05.016

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

Review 1.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

Review 2.  Lipid nanoparticles for gene delivery.

Authors:  Yi Zhao; Leaf Huang
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 3.  Regulation of hepatocyte identity and quiescence.

Authors:  Carmen Berasain; Matías A Avila
Journal:  Cell Mol Life Sci       Date:  2015-06-19       Impact factor: 9.261

4.  Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus.

Authors:  Eun Byul Lee; Jung-Hee Kim; Wonhee Hur; Jung Eun Choi; Sung Min Kim; Dong Jun Park; Byung-Yoon Kang; Gil Won Lee; Seung Kew Yoon
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.